BRANFORD, Conn., Sept. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that Ronit Simantov, M.D., has joined CuraGen as Vice President of Medical Development.
Dr. Simantov is a seasoned and accomplished clinical oncologist with experience obtained in both pharmaceutical and academic positions. In her previous position at Bayer Healthcare Pharmaceuticals, Dr. Simantov played a key role in the successful clinical development, registration, and launch of Nexavar(R) (sorafenib), which was approved by the FDA in 2005. During her academic career, Dr. Simantov conducted research into the modulation of angiogenesis in cancer, and has published extensively in peer-reviewed journals.
"We believe that Ronit has the right expertise to assist us in the evaluation of the data being generated from our three clinical oncology programs, and to support the preparations being made to potentially transition one or more of these products into Phase III during 2008," commented Timothy Shannon, M.D., President and Chief Executive Officer of CuraGen. "Her addition to the team currently in place provides CuraGen with a talented, and very experienced, group of individuals who have a history of successfully bringing products through clinical development and onto market."
Prior to joining CuraGen, Dr. Simantov held positions of increasing
responsibility at Bayer Healthcare Pharmaceuticals from June 2003 through
August 2007, and was most recently Director, Global Clinical Leader,
Oncology during which she was responsible for the global development of
Nexavar(R) in non-small cell lung cancer (NSCLC) and medical lead for
|SOURCE CuraGen Corporation|
Copyright©2007 PR Newswire.
All rights reserved